#USA #New York #Biogen #Alzheimer's #diranersen

Progress in Alzheimer's Research: Biogen's Phase 2 CELIA Study

On May 14, 2026, Biogen unveiled the topline results from its Phase 2 CELIA study of diranersen, an innovative therapy aimed at addressing tau pathology in individuals diagnosed with early Alzheimer's disease. Although the study did not meet its primary endpoint, the findings showcased reductions in tau levels and indicated a possible slowing of cognitive decline in participants. This advancement will lead to further clinical trials for the drug.

Isobel Coleman, CEO of the Alzheimer's Drug Discovery Foundation (ADDF), commented on the significance of these results, highlighting the continued momentum within the Alzheimer's research field. "These findings signal a diversifying approach in Alzheimer's treatment, moving beyond traditional methods to embrace newer strategies that align with the principles of precision medicine," she explained.

With the recent approval of disease-modifying therapies, the continuing efforts boost confidence among stakeholders regarding a future where treatment options can be tailored to individual patient needs. The field has watched progress with amyloid-targeted therapies, and the results from the CELIA study suggest a shift is also possible for tau-targeting therapies. Howard Fillit, MD, co-founder of the ADDF, stated, "Diranersen is a pioneering therapy that demonstrates how lowering tau can yield both biological and clinical benefits, marking a promising leap forward for the field."

As it stands, the search for effective Alzheimer's treatments is gaining steam with several clinical trials underway. Currently, 75% of these studies are focusing on existential pathways aside from amyloid and tau, turning attention to elements like inflammation, metabolic dysfunction, and oxidative stress. The multi-targeted approach is believed to be vital to future Alzheimer's care, aimed at simultaneously tackling the multifaceted nature of this challenging illness.

Data from the CELIA study will be showcased at the forthcoming Alzheimer's Association International Conference (AAIC) scheduled for July 12-16, 2026, in London. This platform will provide the research community with discussions on the implications of these newfound insights and expectations for the treatment landscape ahead.

About the Alzheimer's Drug Discovery Foundation (ADDF)

Established in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation focuses on expediting the development of drugs aimed at preventing, treating, and ultimately curing Alzheimer's disease. The ADDF serves as the only public charity dedicated entirely to this cause, employing a venture philanthropy model to support innovative research within academia and the biotech sector. Through its extensive contributions, the ADDF has significantly impacted the development of crucial diagnostic tools, including the first Alzheimer's PET scan (Amyvid®) and blood test (PrecivityAD®). Over the years, the foundation has allocated approximately $400 million to support 792 programs across 21 nations aimed at drug development, biomarker research, and prevention strategies. For additional details, visit Alzheimer's Drug Discovery Foundation.